Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Li Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2314-8756; OpenAlex author ID A5100418899. Sources: OpenAlex.

Their work

Papers
19 (first author 8, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 3 papers · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper

Papers 19

  1. Deletion of ENO1 sensitizes pancreatic cancer cells to gemcitabine via MYC/RRM1-mediated glycolysis. Co-author DOI 10.1038/s41598-025-94319-0↗
  2. ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway. Co-author DOI 10.1002/mc.23719↗
  3. Correction: Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. First author DOI 10.18632/oncotarget.28527↗
  4. Corrigendum: Establishment of tumor treating fields combined with mild hyperthermia as novel supporting therapy for pancreatic cancer. Co-author DOI 10.3389/fonc.2024.1343421↗
  5. [Corrigendum] Establishment of hypoxia induction in an in vivo animal replacement model for experimental evaluation of pancreatic cancer. First author DOI 10.3892/or.2023.8626↗
  6. Tumor and stroma COL8A1 secretion induces autocrine and paracrine progression signaling in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.matbio.2022.11.002↗
  7. Corrigendum: Establishment of Tumor Treating Fields Combined With Mild Hyperthermia as Novel Supporting Therapy for Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.889215↗
  8. Establishment of Tumor Treating Fields Combined With Mild Hyperthermia as Novel Supporting Therapy for Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.738801↗
  9. Sulforaphane Inhibits the Expression of Long Noncoding RNA H19 and Its Target APOBEC3G and Thereby Pancreatic Cancer Progression. Co-author DOI 10.3390/cancers13040827↗
  10. Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer. First author DOI 10.3390/cancers13194770↗
  11. Mean platelet volume predicts survival in pancreatic cancer patients with synchronous liver metastases. Co-author DOI 10.1038/s41598-018-24539-0↗
  12. Apparent diffusion coefficient (ADC) measurements in pancreatic adenocarcinoma: A preliminary study of the effect of region of interest on ADC values and inter… First author DOI 10.1002/jmri.25007↗
  13. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. First author DOI 10.1016/j.canlet.2016.01.038↗
  14. Genetic variants in the SWI/SNF complex and smoking collaborate to modify the risk of pancreatic cancer in a Chinese population. Co-author DOI 10.1002/mc.22140↗
  15. Comparison of the Diagnostic Performances of Three Techniques of ROI Placement for ADC Measurements in Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.acra.2015.06.017↗
  16. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. First author DOI 10.18632/oncotarget.3171↗
  17. Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication. Co-author DOI 10.18632/oncotarget.1764↗
  18. Establishment of hypoxia induction in an in vivo animal replacement model for experimental evaluation of pancreatic cancer. First author DOI 10.3892/or.2014.3196↗
  19. The functional cytotoxic T lymphocyte-associated Protein 4 49G-to-A genetic variant and risk of pancreatic cancer. Co-author DOI 10.1002/cncr.27455↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ingrid Herr · 12 shared papers, 2014–2024 · strength 1.55
  2. Michael Schaefer · 5 shared papers, 2014–2024 · strength 0.69
  3. Nathalie Bauer · 5 shared papers, 2014–2024 · strength 0.60
  4. Tobias Pfeifer · 3 shared papers, 2021–2024 · strength 0.53
  5. Liping Bai · 3 shared papers, 2021–2024 · strength 0.53
  6. Hongqin Ma · 2 shared papers, 2024–2025 · strength 0.52
  7. Wenxing Zhao · 2 shared papers, 2024–2025 · strength 0.52
  8. Xuefeng An · 3 shared papers, 2021–2022 · strength 0.38
  9. Yiqiao Luo · 3 shared papers, 2021–2022 · strength 0.38
  10. Bin Yan · 3 shared papers, 2021–2022 · strength 0.38
  11. Franco Fortunato · 3 shared papers, 2015–2024 · strength 0.36
  12. Yiyao Zhang · 4 shared papers, 2014–2024 · strength 0.31
  13. Yingpeng Lu · 1 shared paper, 2025 · strength 0.28
  14. Pei Fan · 3 shared papers, 2015–2024 · strength 0.28
  15. Nathalia A. Giese · 3 shared papers, 2014–2024 · strength 0.26
  16. Alexandr V. Bazhin · 2 shared papers, 2015–2024 · strength 0.23
  17. Eduard Ryschich · 2 shared papers, 2015–2024 · strength 0.23
  18. Thilo Hackert · 2 shared papers, 2015–2024 · strength 0.23
  19. Oliver Strobel · 2 shared papers, 2015–2024 · strength 0.23
  20. Matthias M. Gaida · 1 shared paper, 2022 · strength 0.13
  21. Lian Zhao · 1 shared paper, 2022 · strength 0.13
  22. Libo Yin · 1 shared paper, 2021 · strength 0.13
  23. Kangtao Wang · 1 shared paper, 2021 · strength 0.12
  24. Chao Ma · 2 shared papers, 2015–2016 · strength 0.11
  25. Li Wang · 2 shared papers, 2015–2016 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.